Noveome Biotherapeutics, Inc. Initiates Phase 1 Open Label Clinical Trial Evaluating Intranasal Delivery of Lead Candidate ST266 Targeting the Optic Nerve and Brain
Noveome Biotherapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing next-generation biologics for the promotion and restoration of cellular integrity of inflamed or damaged tissues, announced initiation of a Phase 1 open label clinical trial to establish the safety of